<div id="readability-page-1"><p>Craig-Hallum analyst Adam Vogel maintained a Buy rating on Aclaris Therapeutics today and set a price target of $10.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Vogel covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, LB Pharmaceuticals, Inc., and Apogee Therapeutics. According to TipRanks, Vogel has an average return of <span>28.1%</span> and a 93.75% success rate on recommended stocks. </p> <p>In a report released on May 5, Piper Sandler also maintained a Buy rating on the stock with a $11.00 price target.</p></div>

ACRS

LABU

<p>Craig-Hallum analyst Adam Vogel has maintained a Buy rating on Aclaris Therapeutics (ACRS) with a price target of $10.00. Vogel, who focuses on the Healthcare sector, has an average return of 28.1% and a 93.75% success rate on his stock recommendations. Additionally, Piper Sandler also holds a Buy rating on Aclaris with a price target of $11.00.</p>

Tip Ranks

Aclaris Therap

Direxion S&P Biotech Bull 3X

iShares US Pharma

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VG Health

SPDR S&P Biotech

iShares Biotechnology ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

LB Pharmaceuticals

Apogee Therapeutic

Piper Sandler Cos

Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum